All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.
Bookmark this article
Several factors influence the tumor microenvironment (TME) in diffuse large B-cell lymphoma (DLBCL), including genetic factors in lymphoma cells.1 Understanding how these genetic factors influence the TME could identify novel therapeutic targets, and improve the efficacy of immunotherapies, such as chimeric antigen receptor T-cell therapies.1
Here, we summarize a review published by Cerchietti.1 in Blood on the role of genetic drivers of DLBCL in the lymphoma microenvironment (LME).
Using artificial intelligence-based computational analysis of transcriptional signatures, researchers have identified four major categories of LMEs in DLBCL with distinct characteristics (Figure 1):
Figure 1. DLBCL LME categories*
ABC, activated B-cell; BCR, B-cell receptor; CAF, cancer-associated fibroblast; DLBCL, diffuse large B-cell lymphoma; DP, depleted; ECM, extracellular matrix; FDC: follicular dendritic cell; FTH, follicular T-helper cell; FRC, fibroblastic reticular cell; GC, germinal center-like; GCB, germinal center B-cell; IN, inflammatory and immunosuppressive; IRF4, interferon regulatory factor 4; JAK, Janus kinase; LME, lymphoma microenvironment; MDSC, myeloid derived suppressor cell; MS, mesenchymal; NF-Κb, nuclear factor kappa B; NK, natural killer cell; OCT2, organic cation transporter 2; PD-1, programmed cell death-1; PI3K, phosphoinositide 3 kinase; STAT, signal transducer and activator of transcription; TAM, tumor-associated macrophage; TAN, tumor-associated neutrophil; TGF-β, transforming growth factor-β; TNF, tumor necrosis factor; Treg, regulatory T cell; VEC, vascular endothelial cell; VLC, vascular lymphatic cell.
*Adapted from Cerchietti.1
Mutations can affect the TME through several mechanisms, including:
The majority of genetic changes affecting the TME have a combination of direct and indirect, and short- and long-range effects on the TME, and TME changes are often influenced by multiple genetic alterations.
Key learnings |
|
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox